Therapeutic benefit of selective inhibition of p110 PI3-kinase in pancreatic neuroendocrine tumors. Clinical Cancer Research , 2016; DOI: 10.1158/1078-0432.CCR-15-3051 Cite This Page : ...

To test the specificity of PI3K inhibitors in cellular system, we generated a panel of human rhabdomyosarcoma Rh30 cell lines that stably expressed one myristoylation (Myr)-tagged p110 catalytic ...

Karus Therapeutics has announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the ...

DxS has developed a real-time PCR assay using its technologies to detect mutations in the 3 hotspots of the PIK3CA gene and also 1 rare mutation, E545D.

Karus Therapeutics is teaming up with the Babraham Institute to further characterize novel treatments for inflammatory diseases. The partners plan to achieve this through the regulation of ...

(London, April 12) -- A study published by Nature today has defined the function of p110 alpha, the flag-ship molecule of the eight member PI3K family, which is one of the most frequently ...

The p110 alpha and p110 beta isoforms are ubiquitously expressed, and knock-out mice for both are embryonic lethal. 3 It is thought that this widespread functionality of PI3K signaling is at least ...

This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, Feb. 7, 2008, in the JCI, including: VEGF-B helps nerve cells ...

A study published by Nature has defined the function of p110 alpha, the flag-ship molecule of the eight member PI3K family, which is one of the most frequently activated pathways in cancer.

Targeted therapy with imatinib has transformed the treatment of chronic myeloid leukemia (CML). Unlike CML, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration but does demonstrate ...